Bio-Rad Laboratories BIO
$358.90 −$8.60 (-2.34%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $358.90 0.00%
Open$364.34
Prev close$367.50
Day range$353.31 – $369.44
Volume182.3K
Market cap$9.65B
P/E (TTM)9.5
Dividend yield–
BIO Stock News
Headlines matching Bio-Rad Laboratories or the BIO ticker, most recent first.
- Lake Street Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $2
- Huaheng Bio: Implementation and Assessment Management Measures for the 2026 Restricted Stock Incentive Plan of Anhui Huaheng Biotechnology Co., Ltd.
- Citi Initiates Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $12
- L&C BIO Co: Report on Status of Specific Securities, Etc. Owned by Executives and Major Shareholders
- H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $34
- Clear Street Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $38
- Wedbush Maintains Adicet Bio(ACET.US) With Buy Rating, Raises Target Price to $28 Positive
- CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18
- Bio-Rad Laboratories (BIO) Receives a Buy From RBC Capital
- RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Maintains Target Price $390
- RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $390 Positive
- Bio‐Rad Laboratories Balances Recovery And Headwinds In Q2
- Bio-Rad Laboratories | 8-K: Bio-Rad Reports Third -Quarter 2026 Financial Results
- RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $440 Positive
- Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B Vs $2.588B Est
No comments yet — be the first to weigh in on BIO.
Sign in to join the discussion.